Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. Immune-mediated reactions lead to damage to the myelin sheath, and consequently to the axon, which ultimately leads to considerable disability of the patient. The exact cause of the disease is unknown, but it is believed that the appearance of multiple sclerosis is the result of the interaction of genetic and environmental factors. Symptoms by which the disease can be recognized are optic neuritis, limb weakness, gait disturbance and dizziness. The first choice for the treatment of multiple sclerosis is therapy that modifies the course of the disease, or immunomodulation therapy. The immunomodulation approach to treatment reduces the frequency of relapse, slows down the progression of the disease and the number of new lesions. There are currently over 10 drugs approved for the treatment of multiple sclerosis that can be taken intravenously, by injection into a fatty area of the body (subcutaneously), orally or topically. Fingolimod, teriflunomide, and dimethyl fumarate are administered orally, natalizumab, alemtuzumab, and ocrelizumab are administered via intravenous infusion, while interferons are administered by injection. The therapeutic approach is complex and requires an approach to each patient as an individual. Which therapy the patient will receive depends on which criteria for indicating the therapy he meets, and when the criteria are clearly defined, the treatment begins with the first and, if necessary, with the second line of therapy.